PrEP - pre-exposure prophylaxis
Feb 4, 2022 | News
ICAP at Columbia University has added a new video focused on the use of PrEP in Mozambique to its Power of PrEP video series. The video explores how communities throughout the southern African nation can use PrEP (pre-exposure prophylaxis) to prevent acquisition of...
Jan 12, 2022 | Stories from the Field
For community members in Almaty, Kazakhstan, a project to expand HIV health and social assistance services is bringing innovative preventive care to people at risk for HIV. With the support of ICAP, the Almaty Model of HIV Epidemic Control project introduced a new...
Jun 17, 2021 | Stories from the Field
Through the loss of her mother, husband, and two children over a nine-year period, ICAP’s Enala Daudi discovered her purpose as a community health worker—using her lived experiences to accompany her clients throughout their own health journeys after a new HIV...
Jul 7, 2020 | News
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral...
May 19, 2020 | In the Media, News
The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC)...
